RT Journal Article
SR Electronic
T1 2022-RA-647-ESGO Real-word therapy and clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: first description of the SCOUT-1 study centers (NOGGO ov54, NCT04830709)
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A250
OP A250
DO 10.1136/ijgc-2022-ESGO.536
VO 32
IS Suppl 2
A1 Jalid Sehouli
A1 Elena Ioana Braicu
A1 Regina Maria Glowik
A1 Klaus Pietzner
A1 Matthias Rose
A1 Pauline Wimberger
A1 Theresa Link
YR 2022
UL http://ijgc.bmj.com/content/32/Suppl_2/A250.1.abstract
AB Introduction/Background The prospective non-interventional study SCOUT-1 (NOGGO ov54; NCT04830709) investigates clinical real-world management of patients with advanced ovarian cancer in Germany with a special focus on quality of life (QoL) over a study period of seven years.Methodology All sites initiated through March 2022 were invited to document the cumulative number and characteristics of their OC patients treated in 2021. Details on site type and certification were also collected. The analysis has a descriptive and exploratory character. The variables are summarized using appropriate statistical methods.Results Until April 1st, 2022, 47 sites provided cumulative data: 36 (77%) full-service hospitals (university hospital, hospital with maximum or specialized care), 3 (6%) base service hospitals, and 8 (17%) office-based (gyneco)oncological sites. Majority of participating sites are certified (gyneco)oncological centres according the German Cancer Society. Each site treated on average 28 patients with 1L OC in 2021, with a large range of 4–127 patients (13% treated < 1 patient/month, 45% 1–2 patients/month and 43% >2 patients/month). The sites mainly diagnosed advanced stage FIGO III or IV disease (74%), serous histology (71%) and high-grade carcinoma (75%). Most patients received cytoreductive surgery. The majority of patients (80%) received and responded to platinum-based chemotherapy.Conclusion The analysis of cumulative data is in line with other epidemiologic sources in Germany and reflects a potential to enroll a representative cohort of patients with advanced OC in the SCOUT-1 study. Study is ongoing and is open for recruitment.